Sai Life Sciences Limited has informed the Exchange about Investor Presentation
Date: 14 May 2025
To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: SaiLife
To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 BSE Scrip Code: 544306
Sub: Investor Presentation for the year ended 31 March 2025
Dear Sir/ Madam,
With reference to the above subject, we enclose herewith the Investor Presentation for the year ended 31 March 2025.
We request you to take note of the same and oblige.
Thank you.
For Sai Life Sciences Limited
____________________________ Runa Karan Company Secretary & Compliance Officer Membership No.: A13721
Encl: As above
Sai Life Sciences Limited (CIN: U24110TG1999PLC030970)
Corporate office
Registered office
# L4-01 & 02, SLN Terminus, Survey #133, Gachibowli Miyapur Road, Gachibowli, Hyderabad – 500032, Telangana, India.
Plot No. DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri (Dist), Hyderabad -500078, Telangana, India.
Contact us T: +91 40 6815 6000, F: +91 40 6815 6199 E: info@sailife.com W: www.sailife.com
Sai Life Sciences Limited
Earnings Presentation
May 14, 2025
Safe Harbour
Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include
words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate",
"intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar
expressions of such expressions may constitute "forward-looking statements", These forward looking statements involve a number of
risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking
statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth
and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income,
cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update
forward-looking statements to reflect events or circumstances after the date thereof.
2
Message from Managing Director & CEO
“
We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity
expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add
value, helping us deliver seamless solutions across the drug development lifecycle to our global and biotech
partners.
One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the
growing demand for complex peptide synthesis and conjugation. This investment marks another step
forward in strengthening our capabilities to support next-generation therapeutics.
Mr. Krishna Kanumuri
MD & CEO
With India emerging as a strategic hub in global drug development, Sai Life Sciences is well-positioned to
tap into new growth opportunities. We remain focused on investing in technology, infrastructure, and talent
to stay aligned with the evolving needs of our clients.
As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver
lasting value to our stakeholders “
3
Message from Chief Financial Officer
“
We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments.
Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by lower finance costs and operating leverage. With the completion of our planned ₹720 Cr debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26.
Capex for the year stood at ₹ 408Cr, focused on enhancing our manufacturing footprint and expanding discovery capabilities.
Mr. Siva Chittor
CFO
We remain committed to disciplined execution and prudent capital allocation as we continue to build on our growth momentum and deliver long-term value to stakeholders.
“
4
Performance Highlights
Robust Yearly Financial Performance
Revenue (₹ Cr)
Material Margin (₹ Cr) and Margin (%)
1,695
1,465
1,217
870
69%
603
65%
795
70%
1,019
73%
1,229
FY22
FY23
FY24
FY25
FY22
FY23
FY24
FY25
EBITDA (₹ Cr) and Margin (%)
PAT (₹ Cr) and Margin (%)
25%
425
21%
300
15%
131
15%
182
10%
170
6%
83
1%
1%
6
10
FY22
FY23
FY24
FY25
FY22
FY23
FY24
FY25
6
Segmental Performance: CDMO & CRO
CDMO
CRO
148
123
CDMO (₹ Cr)
257
240
267
276
405
321
63%
FY25 Revenue Contribution
37%
Q1
Q2
Q3
Q4
CRO (₹ Cr)
135
132
156
127
164
117
174
118
• Both CDMO and CRO businesses continue to demonstrate growth momentum, supported by increased business from existing customers and new collaboration
Q1
Q2
Q3
Q4
FY24
FY25
7
Financial Ratios Overview
ROCE
Gross Fixed Asset Turnover
Inventory Days
12.3%
10.3%
69.0%
85.8%
87.3%
80.1%
139
115
93
81
5.1%
3.2%
FY22
FY23
FY24
FY25
FY22
FY23
FY24
FY25
FY22
FY23
FY24
FY25
Net Debt/ Equity (x)
Net Debt/ EBITDA (x)
Net Working Capital Days
0.84
0.80
0.75
5.6
204
3.9
2.4
140
122
117
FY22
FY23
FY24
FY25
-0.04
FY22
FY23
FY24
FY25 -0.2
FY22
FY23
FY24
FY25
8
Sai Life Sciences Corporate Overview
Sai Life Sciences is driven by the eternal teachings of the Saint of Shirdi, from whom we derive our name
Shraddha - an intense belief or conviction We uphold a sense of Shraddha towards our purpose of using science to accelerate solutions for improving life.
Belief
Our Core Values
Integrity
Ownership
Respect
Transparency
Reliability
Collaboration
Perseverance
Saburi - perseverance or patience We strive for Saburi to stay the course with our partners till we achieve our goals.
10
We aspire to be the pre-eminent CRDMO partner for global innovators in the Asia-Pacific region
Leading Asian CRDMOs grew rapidly during the period from 2018 to 2022, on the back of aggressive Capex investments.
Today, India stands at the threshold of a similar opportunity with macro trends pointing to a rebalancing of global offshoring towards the Asian region.
Sai Life Sciences benchmarks itself with the best of global players in building its scientific, technological, operational, regulatory and sustainability capabilities.
Sai Life Sciences continues to invest in:
•
Increasing R&D and Manufacturing capacity
• Talent pool with niche capabilities
• New technologies & modalities
• Automation and Digitalization
• Health, Safety & Environmental practices
11
Corporate Overview
Two business verticals Discovery and Chemistry, Manufacturing, & Controls (CMC)
4 Global sites; 3000+ employees
Excellence in Sustainability
10+ Years Enduring customer relationships
100% Revenues from NCEs serving highly regulated markets such as US, UK, EU & Japan
Diverse Therapy Areas Oncology, CNS, Inflammation, Antivirals, Rare diseases, and more
Focus on Complex Chemistry and new modalities
USFDA, PMDA 100% successful regulatory record
Sai Life Sciences was the first Indian company to join the PSCI membership
25+ year track record of delivery
300+ Innovator clients including 18 of the top 25 big pharma
Diverse client profile Biotech, small & mid and big pharma
12
The CRDMO industry is a Service Business with value drivers different from generic pharma companies
"As a CRDMO, our value doesn’t hinge on drug approvals—we’re not in the business of binary outcomes. We generate consistent, scalable value through scientific depth, execution reliability, and long-term client partnerships.”
Krishna Kanumuri MD & CEO, Sai Life Sciences
Sai Life Sciences is an Associate Member of ACS- Green Chemistry Institute Pharmaceutical Roundtable
• R&D investments in drug discovery / development program
translate to revenue opportunities for CRDMOs – irrespective of whether it receives approval or not
• Stage-gating decisions rest with the innovator (clients)
• Given the multitude of factors involved, the success or failure of a
molecule is never directly attributed to the CRDMO.
• CRDMOs are purely judged by the quality of work they render
within the scope of the defined project
13
Value drivers for CRDMO companies
• Culture & value system
• R&D problem-solving abilities
• Ability to scale up novel chemistry at speed
• GMP capability and Quality systems
• Safety & Sustainability practices
• Ability to attract and nurture top talent
14
Typical journey of bringing a new drug to market
Involves screening for potentially active compounds that have a therapeutic effect on an intended disease
Time frame: 7-12 years
"As a CRDMO, our value doesn’t hinge on drug approvals—we’re not in the business of binary outcomes. We generate consistent, scalable value through scientific depth, execution reliability, and long-term client partnerships.”
Value of services: > 50%
Substances identified are refined, optimized, and ex- tensively tested to provide sufficient evidence of safety and efficacy before trials in humans can begin
Compounds evaluated: > 10000
Investment: US$ 1-2 Billion
Research studies involving human volunteers to evaluate the safety, efficacy, and outcomes of the drug candidates. Clinical trials consist of four phases with progressively larger numbers of volunteers.
– Krishna Kanumuri MD & CEO, Sai Life Sciences
Data from Clinical Trials is collected, analyzed and submitted to ap- propriate authorities for review and approval.
15
Generalized representation for illustrative purposes only
*Source: Internal research
Sai Life Sciences has solutions that support pharmaceutical innovators along the entire drug discovery journey
Stage 1 Early Drug Discovery
Stage 2 Pre-Clinical Phase
Discovery
Target Validation to Lead Candidate
Lead Identified to First -Time-In-Human Trials
Sai Life Sciences has a play in the monetization opportunities across the journey
"As a CRDMO, our value doesn’t hinge on drug approvals—we’re not in the business of binary outcomes. We generate consistent, scalable value through scientific depth, execution reliability, and long-term client partnerships.”
Process Development Clinical supplies
Early Phase (FTIH) to Late Phase Clinical Supplies
– Krishna Kanumuri MD & CEO, Sai Life Sciences
Stage 3 Clinical Phase
Regulatory Approval
Approval for Commercialization
Commercial Manufacturing
Late Phase through to Validation & Filing
Life Cycle Management of Commercialised products
16
World-class R&D and Manufacturing facilities in key locations globally
Global Delivery Model
Process R&D Lab in Alderley Park | 65 Employees
R&D and manufacturing capacity expansion underway in India around existing sites.
Through a strategic mix of onshore and offshore resources, we provide our clients the expertise and proximity of onshore teams combined with the cost- effectiveness and scalability of offshore operations.
"As a CRDMO, our value doesn’t hinge on drug approvals—we’re not in the business of binary outcomes. We generate consistent, scalable value through scientific depth, execution reliability, and long-term client partnerships.”
700 KL GMP Manufacturing | 900 employees
• Business Development
– Krishna Kanumuri MD & CEO, Sai Life Sciences
Presence in all major life sciences hubs globally.
Exploratory Biology Lab in the Cambridge-Boston Life Sciences ecosystem | 25 employees
13-acre Integrated R&D Campus in Genome Valley | 1800 employees
• Sourcing office in Beijing
China
17
Discovery Overview
• Capabilities spanning Target Validation to IND
•
•
300+ programs successfully delivered
Integrated services: Medicinal Chemistry & Synthetic Chemistry, CADD, Biology, DMPK & Toxicology
• > 65% Integrated Programs in current portfolio
• Diverse Therapeutic Experience
•
programs
25 in last 2 years
advanced
to
development
stage
• Expanding capabilities in ADCs, TPDs, Peptides, CGTs,
Oligos, and more.
• Flexible engagement models and collaborative mindset
• Enduring client relationships
18
ISO 14001:2015, ISO 45001:2018 & ISO 50001: 2018 certification
Certificate of Registration: Information Security Management System – ISO/IEC 27001:2013
467
497
626
274
189
FY21
FY22
FY23
FY24
FY25
Discovery Revenues (INR Cr.)
CMC Overview
• End-to-End capabilities from IND through
to commercialization
• Focus on Complex Chemistry, ADC Payloads & Linkers
• Modern, GMP-compliant facilities across UK and India
• Flexibility to support both small-scale clinical supplies and
large-scale commercial production.
• Proven track record of commercializing NCEs
• Robust regulatory record with USFDA and PMDA
• 90+ Programs in the pipeline across multiple therapy
areas
• Clear Regulatory Record: USFDA, PMDA
• At the forefront of digitalization, automation
and sustainability
19
Eco Vadis Silver Medal for Sustainability
Signatory of United Nations Global Compact (UNGC)
968
1068
571
596
750
FY21
FY22
FY23
FY24
FY25
CMC Revenues (INR Cr.)
Consolidated Statement of Profit and Loss
Particulars (₹ crores)
Revenue from operations
Other income
Total income
Expenses
Cost of materials consumed and changes in inventories
Employee benefits expense
Other expenses
Forex exchange (gain)/loss
EBITDA
EBITDA Margin
Finance costs
Depreciation and amortisation expense
Profit before tax
Total Tax expense
Profit after tax
20
Q4FY25
Q3FY25
Q4FY24
580
6
586
168
151
103
-3
161
28%
11
37
119
31
88
440
4
449
121
133
66
-5
124
28%
23
34
72
18
54
439
3
443
124
131
60
0
125
28%
21
31
76
20
56
FY25
1695
18
1712
466
549
274
-19
425
25%
76
139
228
58
170
FY24
1465
14
1494
446
495
239
-15
300
20%
86
119
109
26
83
Thank You
For more details please contact:
Investorrelation@sailife.com
© Sai Life Sciences Limited.
L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India.
Glossary
APIs
Biotechs
Active pharmaceutical ingredients
Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug development technologies to address unmet medical needs
Blockbuster End Molecules Blockbusters are drug products with annual sales of over US$1 billion in the Financial Year 2023
CDSCO
CMC / CDMO
CMO
Central Drug Standards Control Organization, India
Chemistry, Manufacturing and Control / Contract Development and Manufacturing Organization
Contract Manufacturing Organization
COFEPRIS Mexico
Federal Commission for the Protection against Sanitary Risk of Mexico
CRDMO
CRO
DMPK
GATT
Contract Research, Development, And Manufacturing Organization
Contract Research Organization
Drug metabolism and pharmacokinetics
General Agreement on Tariffs and Trade
Generic drugs
Refer to pharmaceutical drugs that have the same chemical composition as the original innovator drug and can be sold by companies after the patent on the original drug expires
Innovation Clusters/Hubs
Nine regions identified by Frost and Sullivan including Boston/Cambridge in Massachusetts, Manchester/London/Cambridge in UK, Chicago in Illinois, New Jersey, New York, Paris in France, Switzerland and Japan. In 2022, approximately 57% of global R&D spending were in these nine pharma hubs
Innovator Drugs
Refer to first drugs created containing specific active ingredients and undergo approval or patent process for use
Large Molecule
Have a large molecular weight and made of proteins that are complex in structure compared to small molecule drugs. Costly to manufacture and, at this time, in most cases can only be administered by injection or infusion. Typically manufactured biologically, i.e. extracted from living organisms, but often include certain synthetic chemistry processes
Large Pharma Companies
Pharma companies with revenues > USD 10 billion
Mid Pharma Companies
Pharma companies with revenues in range of USD 500 million to USD 10 billion
NCE
PMDA
Small Molecule
New chemical entities
Pharmaceuticals and Medical Devices Agency, Japan
Organic compound with low molecular weight, small molecule drugs are known for their affordability, ease of administration (largely orally), and broad therapeutic coverage. Typically manufactured using synthetic chemistry processes
Small Pharma Companies
Pharma companies with revenues lower than USD 500 million
TRIPS
USFDA
22
Trade-Related Aspects of Intellectual Property Rights
United States Food and Drug Administration